DigiMed Bayern

DigiMed Bayern for the Medicine of the Future

Homepage of the Project: www.digimed-bayern.de


P4 medicine (predictive, preventive, personalized, participatory) is one of the world's most promising developments for improved, holistic and efficient health care. DigiMed Bayern's goal is to guide Bavaria into this medicine of the future with a flagship project.

The flagship P4-medicine project DigiMed Bayern has been funded by the Bavarian Ministry of Health and Care with around 24.5 million
euros since 2018. DigiMed Bayern combines comprehensive datasets of patients diagnosed with atherosclerotic diseases, such as coronary heart disease and stroke, or with genetic risk factors. This dataset will be further enriched with state-of-the-art multi-dimensional molecular characterization (-omics technologies) of associated sample material. For the integrative analysis of the resulting "Big Data", an ethically and legally compliant, highly secure and sustainable IT infrastructure will be fundamentally designed and implemented. Finally, patients and persons at risk will benefit from advancements in disease risk prediction, targeted prevention, diagnosis and treatment.

Superior goals of DigiMed Bayern

1.    Using the example of atherosclerosis, a first analysis of comprehensive data sets in the sense of digital medicine of the future is carried out. All those involved in the health care system in Bavaria should benefit directly: the prediction for coronary heart disease (CHD) and stroke should be made more accurate in the short term and preventive treatment should be improved. In the medium to long term improvements in diagnosis and therapy are pursued. The population-wide identification of familial hypercholesterinemia as an exemplary risk factor for atherosclerosis should be sustainably improved.
2.    The technical, legal and social possibilities and limitations of P4 medicine are recorded, promoted and documented by means of concrete implementation. This includes a proactive multi-directional information exchange with all those involved in health, with a focus on systemic development.
3.    Resulting insights and structures should be expandable in the health system, in research and in the economy and be transferable to other diseases. In particular, an exemplary and transferable integrated digital infrastructure should be created.
4.    Bavaria as a location for P4 medicine should be substantially developed, including international perception and internationally networking.


Planned duration:
Q4 2018 to Q4 2024


Scientific Directorate:   
German Heart Centre Munich

Managing Directorate:   
BioM Biotech Cluster Development GmbH

Initially involved Institutions   

    More information:

    Homepage of the Project: www.digimed-bayern.de

    Dr. Jens Wiehler
    Dr. Jens Wiehler

    Digital Health Lead, Managing Director DigiMed Bayern

    Anja Kroke
    Anja Kroke

    Event Manager

    project funded by: